I. Nunes

发表

Plasminogen/plasminogen activator and growth factor activation.

D. Rifkin, P. Gleizes, R. Mazzieri, 1997, Ciba Foundation symposium.

Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals.

D. Rifkin, D. Roses, R. Shapiro, 1996, Cancer research.

C-Abl Is Required for the Development of Hyperoxia-Induced Retinopathy

S. Goff, L. Zanetta, R. Higgins, 2001, Journal of Experimental Medicine.

Structure and activation of the large latent transforming growth factor-beta complex.

D. Rifkin, P. Gleizes, R. Shapiro, 1996, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

HL-60 Cells on Growth and Differentiation of Retinoic Acid-treated β Factor-Effects of Endogenously Activated Transforming Growth

D. Rifkin, S. Kojima, I. Nunes, 2006 .

Effects of endogenously activated transforming growth factor-beta on growth and differentiation of retinoic acid-treated HL-60 cells.

D. Rifkin, S. Kojima, I. Nunes, 1996, Cancer research.

TGF-beta latency: biological significance and mechanisms of activation.

D. Rifkin, P. Gleizes, R. Mazzieri, 1997, Stem cells.

Urokinase-type plasminogen activator-deficient mice are predisposed to staphylococcal botryomycosis, pleuritis, and effacement of lymphoid follicles.

D. Rifkin, D. Roses, R. Shapiro, 1997, The American journal of pathology.

Catalase enrichment using recombinant adenovirus protects αTN4-1 cells from H2O2

A. Spector, C. Young, I. Nunes, 2006 .

An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct.

D. Rifkin, C. Metz, D. Loskutoff, 1994, Analytical biochemistry.

Effect of temozolomide on the U-118 glioma cell line.

M. Lopes, A. Carmo, I. Crespo, 2011, Oncology letters.

Pitx3 is required for development of substantia nigra dopaminergic neurons

Robert E. Burke, Robert M. Silva, R. Burke, 2003, Proceedings of the National Academy of Sciences of the United States of America.

Latent transforming growth factor-beta: structural features and mechanisms of activation.

D. Rifkin, P. Gleizes, R. Mazzieri, 1997, Kidney international.

Latent Transforming Growth Factor-β Binding Protein Domains Involved in Activation and Transglutaminase-dependent Cross-Linking of Latent Transforming Growth Factor-β

D. Rifkin, P. Gleizes, C. Metz, 1997, The Journal of cell biology.

TGF‐β Latency: Biological Significance and Mechanisms of Activation

D. Rifkin, P. Gleizes, R. Mazzieri, 1997 .

GRIFIN, a Novel Lens-specific Protein Related to the Galectin Family*

R. Hegde, R. Lang, I. Nunes, 1998, The Journal of Biological Chemistry.

Characterization of latent TGF-beta activation by murine peritoneal macrophages.

D. Rifkin, R. Shapiro, I. Nunes, 1995, Journal of immunology.

NF-κB activity is constitutively elevated in c-Abl null fibroblasts

S. Goff, Rachel A. Liberatore, I. Nunes, 2009, Proceedings of the National Academy of Sciences.

Catalase enrichment using recombinant adenovirus protects alphaTN4-1 cells from H(2)O(2).

A. Spector, C. Young, I. Nunes, 2006, Free Radical Biology & Medicine.

Structure and activation of the large latent transforming growth factor-Beta complex.

D. Rifkin, P. Gleizes, R. Shapiro, 1996, Journal of the American Optometric Association.